480 related articles for article (PubMed ID: 25004111)
41. Hymenoptera venom immunotherapy: Safety and efficacy of an accelerated induction regimen with depot aluminum adsorbed extracts.
Brunetto S; Gammeri L; Buta F; Gangemi S; Ricciardi L
Allergy Asthma Proc; 2024 May; 45(3):195-200. PubMed ID: 38755779
[No Abstract] [Full Text] [Related]
42. Prevalence of hymenoptera venom allergy and poor adherence to immunotherapy in Austria.
Bokanovic D; Aberer W; Griesbacher A; Sturm GJ
Allergy; 2011 Oct; 66(10):1395-6. PubMed ID: 21635267
[No Abstract] [Full Text] [Related]
43. Predictors of clinical effectiveness of Hymenoptera venom immunotherapy.
Ruëff F; Vos B; Oude Elberink J; Bender A; Chatelain R; Dugas-Breit S; Horny HP; Küchenhoff H; Linhardt A; Mastnik S; Sotlar K; Stretz E; Vollrath R; Przybilla B; Flaig M
Clin Exp Allergy; 2014; 44(5):736-46. PubMed ID: 24447114
[TBL] [Abstract][Full Text] [Related]
44. Immunotherapy and biologicals for the treatment of allergy to Hymenoptera stings.
Ridolo E; Pellicelli I; Kihlgren P; Nizi MC; Pucciarini F; Senna G; Incorvaia C
Expert Opin Biol Ther; 2019 Sep; 19(9):919-925. PubMed ID: 31190572
[No Abstract] [Full Text] [Related]
45. Basophil Activation Test in Double-Sensitized Patients With Hymenoptera Venom Allergy: Additional Benefit of Component-Resolved Diagnostics.
Schmidle P; Blank S; Altrichter S; Hoetzenecker W; Brockow K; Darsow U; Biedermann T; Eberlein B
J Allergy Clin Immunol Pract; 2023 Sep; 11(9):2890-2899.e2. PubMed ID: 37302791
[TBL] [Abstract][Full Text] [Related]
46. Vespa velutina nigrithorax venom allergy: inhibition studies approach for the choice of specific immunotherapy.
Grossi V; Severino M; Massolo A; Infantino M; Laureti F; Macchia D; Meucci E; Francescato E; Pantera B; Ebbli A; Fumagalli F; Lari B; Perri A; Liotti I; Ciotta G; Terenzi G; Valeva SV; Consolati M; Folgore T; Manfredi M
Eur Ann Allergy Clin Immunol; 2023 Jul; 55(4):161-165. PubMed ID: 36515256
[No Abstract] [Full Text] [Related]
47. Basophil-activation tests in Hymenoptera allergy.
Dubois AE; van der Heide S
Curr Opin Allergy Clin Immunol; 2007 Aug; 7(4):346-9. PubMed ID: 17620828
[TBL] [Abstract][Full Text] [Related]
48. Venom immunotherapy in patients with clonal mast cell disorders: efficacy, safety, and practical considerations.
Bonadonna P; Gonzalez-de-Olano D; Zanotti R; Riccio A; De Ferrari L; Lombardo C; Rogkakou A; Escribano L; Alvarez-Twose I; Matito A; Vega A; Passalacqua G
J Allergy Clin Immunol Pract; 2013; 1(5):474-8. PubMed ID: 24565619
[TBL] [Abstract][Full Text] [Related]
49. [Side effects of specific immunotherapy in patients with hymenoptera venom allergy].
Lata J; Specjalski K; Kołaczkowska M; Chełmińska M; Niedoszytko M; Jassem E
Pneumonol Alergol Pol; 2005; 73(3):260-3. PubMed ID: 16989163
[TBL] [Abstract][Full Text] [Related]
50. Safety profile of hymenoptera venom immunotherapy (VIT) in monosensitized patients: lack of new sensitization to nontreated insect venom.
Spoerl D; Bircher AJ; Scherer K
J Investig Allergol Clin Immunol; 2011; 21(1):22-7. PubMed ID: 21370719
[TBL] [Abstract][Full Text] [Related]
51. Hymenoptera venom allergy: work disability and occupational impact of venom immunotherapy.
Paolocci G; Folletti I; Torén K; Muzi G; Murgia N
BMJ Open; 2014 Aug; 4(8):e005593. PubMed ID: 25099935
[TBL] [Abstract][Full Text] [Related]
52. Efficacy and safety of rush immunotherapy in patients with Hymenoptera allergy in Japan.
Hirata H; Asakura T; Arima M; Cheng G; Honda K; Fukushima F; Yamaguchi B; Yoshida N; Fukuda T
Asian Pac J Allergy Immunol; 2003 Jun; 21(2):89-94. PubMed ID: 14629126
[TBL] [Abstract][Full Text] [Related]
53. Clinical aspects of hymenoptera venom allergy and venom immunotherapy.
Bilò MB; Tontini C; Martini M; Corsi A; Agolini S; Antonicelli L
Eur Ann Allergy Clin Immunol; 2019 Nov; 51(6):244-258. PubMed ID: 31594296
[TBL] [Abstract][Full Text] [Related]
54. Natural history of Hymenoptera venom allergy in children not treated with immunotherapy.
Lange J; Cichocka-Jarosz E; Marczak H; Krauze A; Tarczoń I; Świebocka E; Lis G; Brzyski P; Nowak-Węgrzyn A
Ann Allergy Asthma Immunol; 2016 Mar; 116(3):225-9. PubMed ID: 26945496
[TBL] [Abstract][Full Text] [Related]
55. Tolerated sting challenge in patients on Hymenoptera venom immunotherapy improves health-related quality of life.
Koschel DS; Schmies M; Weber CN; Höffken G; Balck F
J Investig Allergol Clin Immunol; 2014; 24(4):226-30. PubMed ID: 25219104
[TBL] [Abstract][Full Text] [Related]
56. Hymenoptera venom immunotherapy.
Bilò BM; Bonifazi F
Immunotherapy; 2011 Feb; 3(2):229-46. PubMed ID: 21322761
[TBL] [Abstract][Full Text] [Related]
57. A 5-year venom immunotherapy protocol with 50 μg maintenance dose: safety and efficacy in school children.
Konstantinou GN; Manoussakis E; Douladiris N; Hatziioannou A; Giavi S; Saxoni-Papageorgiou P; Papadopoulos NG
Pediatr Allergy Immunol; 2011 Jun; 22(4):393-7. PubMed ID: 21235631
[TBL] [Abstract][Full Text] [Related]
58. Wasp venom immunotherapy induces a shift from IL-4-producing towards interferon-gamma-producing CD4+ and CD8+ T lymphocytes.
Schuerwegh AJ; De Clerck LS; Bridts CH; Stevens WJ
Clin Exp Allergy; 2001 May; 31(5):740-6. PubMed ID: 11422133
[TBL] [Abstract][Full Text] [Related]
59. Bee venom immunotherapy induces a shift in cytokine responses from a TH-2 to a TH-1 dominant pattern: comparison of rush and conventional immunotherapy.
McHugh SM; Deighton J; Stewart AG; Lachmann PJ; Ewan PW
Clin Exp Allergy; 1995 Sep; 25(9):828-38. PubMed ID: 8564721
[TBL] [Abstract][Full Text] [Related]
60. Skin Test Reactivity to Hymenoptera Venom after Venom Immunotherapy Correlates Inversely with the IgG/IgE Ratio.
Saulite I; Hoetzenecker W; Guenova E; Schmid-Grendelmeier P; Glatz M
Int Arch Allergy Immunol; 2017; 174(3-4):190-199. PubMed ID: 29130986
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
